These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 3128783)

  • 1. Biologic activities of interleukin-1 relevant to rheumatic diseases.
    Miller LC; Dinarello CA
    Pathol Immunopathol Res; 1987; 6(1):22-36. PubMed ID: 3128783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokines in rheumatic diseases.
    Miller LC
    Biotherapy; 1994; 8(2):99-111. PubMed ID: 8924358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment.
    Soltész P; Kerekes G; Dér H; Szücs G; Szántó S; Kiss E; Bodolay E; Zeher M; Timár O; Szodoray P; Szegedi G; Szekanecz Z
    Autoimmun Rev; 2011 May; 10(7):416-25. PubMed ID: 21281743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Actual status of antiinterleukin-1 therapies in rheumatic diseases.
    Geyer M; Müller-Ladner U
    Curr Opin Rheumatol; 2010 May; 22(3):246-51. PubMed ID: 20150813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Off-label use of anti-IL-1 drugs in rheumatic diseases.
    Stefania S; Colia R; Cinzia R; Corrado A; Cantatore FP
    Int J Immunopathol Pharmacol; 2021; 35():20587384211006584. PubMed ID: 33855881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulation in rheumatic and related diseases.
    Russell RG
    Mt Sinai J Med; 1990 Oct; 57(5):305-10. PubMed ID: 2096277
    [No Abstract]   [Full Text] [Related]  

  • 7. The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases.
    Gasparyan AY; Stavropoulos-Kalinoglou A; Mikhailidis DP; Toms TE; Douglas KM; Kitas GD
    Curr Vasc Pharmacol; 2010 Jul; 8(4):437-49. PubMed ID: 19758114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proinflammatory cytokines (IL-12 and IL-18) in immune rheumatic diseases: relation with disease activity and autoantibodies production.
    Mosaad YM; Metwally SS; Auf FA; AbdEL-Samee ER; el-Deek B; Limon NI; el-Chennawi FA
    Egypt J Immunol; 2003; 10(2):19-26. PubMed ID: 15719608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies.
    Cavalli G; Dinarello CA
    Rheumatology (Oxford); 2015 Dec; 54(12):2134-44. PubMed ID: 26209330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin D and rheumatic diseases.
    Rossini M; Gatti D; Viapiana O; Caimmi C; Idolazzi L; Fracassi E; Adami S
    Reumatismo; 2014 Jul; 66(2):153-70. PubMed ID: 25069497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cell subsets and their role in the pathogenesis of rheumatic disease.
    Gizinski AM; Fox DA
    Curr Opin Rheumatol; 2014 Mar; 26(2):204-10. PubMed ID: 24445478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-6 biology: implications for clinical targeting in rheumatic disease.
    Calabrese LH; Rose-John S
    Nat Rev Rheumatol; 2014 Dec; 10(12):720-7. PubMed ID: 25136784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fever in various rheumatic diseases.
    Weinberger A; Kesler A; Pinkhas J
    Clin Rheumatol; 1985 Sep; 4(3):258-66. PubMed ID: 2415294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-1: biology, pathophysiology, and clinical prospects.
    Platanias LC; Vogelzang NJ
    Am J Med; 1990 Nov; 89(5):621-9. PubMed ID: 2239982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-inflammatory panacea? The expanding therapeutics of interleukin-1 blockade.
    Kahlenberg JM
    Curr Opin Rheumatol; 2016 May; 28(3):197-203. PubMed ID: 26859478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. At the horizon of innovative therapy in rheumatology: new biologic agents.
    Finckh A; Gabay C
    Curr Opin Rheumatol; 2008 May; 20(3):269-75. PubMed ID: 18388517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wnt pathway and IL-17: novel regulators of joint remodeling in rheumatic diseases. Looking beyond the RANK-RANKL-OPG axis.
    Daoussis D; Andonopoulos AP; Liossis SN
    Semin Arthritis Rheum; 2010 Apr; 39(5):369-83. PubMed ID: 19095294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Follicular T helper cells and IL-21 in rheumatic diseases.
    Rasmussen TK
    Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic rheumatic diseases: From biological agents to small molecules.
    Sarzi-Puttini P; Ceribelli A; Marotto D; Batticciotto A; Atzeni F
    Autoimmun Rev; 2019 Jun; 18(6):583-592. PubMed ID: 30959214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autophagy: controlling cell fate in rheumatic diseases.
    Rockel JS; Kapoor M
    Nat Rev Rheumatol; 2016 Sep; 12(9):517-31. PubMed ID: 27334205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.